Mineralys achieved positive Phase 2 results in CKD patients with hypertension. Click here to find out why MLYS stock is a ...
The new drug Baxdrostat lowers resistant hypertension in difficult-to-treat patients, showing promising results in a global ...
Topline results from the EXPLORE-OSA trial are anticipated in 1Q 2026 ~RADNOR, Pa., Sept (GLOBE NEWSWIRE) -- Mineralys ...
We recently compiled a list of the 12 Best Performing Healthcare Stocks to Buy Right Now. Mineralys Therapeutics, Inc. is one ...
The emerging role of aldosterone in hypertension and cardiovascular diseases has prompted a renewal of interest in therapeutic approaches designed to interfere with the action of this ...
An investigational antihypertensive agent that inhibits the enzyme involved in aldosterone production, called MLS-101, significantly reduces blood pressure in patients with uncontrolled and resistant ...
Dr. Aaronson answers the question: 'What Is An Aldosterone Antagonist?' — -- Question: What is an aldosterone antagonist, how does it work, and when is it used to treat heart failure? Answer: ...
Elevated aldosterone levels may contribute to left ventricular (LV) structural remodeling post myocardial infarction (MI) and in patients with advanced heart failure, and aldosterone receptor blockade ...
Type 2 diabetes (T2D) incidence continues to rise among African Americans (AAs). However, it has been observed to plateau among non-Hispanic whites (NHWs). Moreover, T2D-associated mortality and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback